15 results about "Epirubicin" patented technology

The application provides a SERS substrate and a detection method for epirubicin blood drug concentration, and belongs to the technical field of detection. ‑1 The characteristic peak intensity is determined. By establishing a quantitative curve of the epirubicin concentration in serum and the peak intensity, rapid quantitative detection of clinical samples is realized. The method has simple sample processing, high detection sensitivity, good repeatability, is consistent with the LC-MS / MS result, and is suitable for bedside treatment drug monitoring.

A kind of epirubicin prodrug, albumin nanoparticle pharmaceutical composition comprising the prodrug and its preparation method and application.The long-chain fatty acid is connected with epirubicin by using acyl hydrazone bond sensitive to tumor acid microenvironment to construct epirubicin prodrug, so as to improve the binding capacity of epirubicin and albumin.The prepared epirubicin prodrug can realize the sufficient dissolution of prodrug using water as solvent, then mixed with albumin aqueous solution, and after high pressure homogenization, the uniformly distributed epirubicin-fatty acid prodrug albumin nanoparticle pharmaceutical composition can be obtained.The preparation process provided does not need to use organic solvent, breaks through the technical obstacle that existing albumin preparation product must use organic solvent to prepare, simplifies the preparation process, and at the same time avoids the risk of organic solvent residue and inducing albumin denaturation.

The application belongs to the technical field of chemical synthesis, and particularly relates to an intermediate compound II of epirubicin hydrochloride; a synthesis method of the intermediate compound II of epirubicin hydrochloride comprises the following steps: dissolving compound I in an organic solvent A, adding iodobenzene diacetate, controlling temperature to react, after the reaction is completed, extracting with an extracting agent, collecting an organic layer, concentrating, adding a crystallization solvent 1 to crystallize, performing suction filtration, and drying to obtain the intermediate compound II; the compound is used to prepare epirubicin, the route operation is simple, the safety of operation is improved, production cost is saved, and the method is more suitable for industrial production; the target product prepared by the method has high purity and yield, and can overcome defects of the prior art, such as complicated operation, high production cost, high technical requirement and the like.

The invention provides an SERS (Surface Enhanced Raman Scattering) substrate and a detection method for the blood concentration of epirubicin, and belongs to the technical field of detection.The SERS substrate is prepared by the following steps: firstly, respectively preparing 40nm and 20nm gold nanoparticles through a sodium citrate reduction method, and constructing the SERS substrate on a silicon dioxide sheet through ABA sandwich dispensing; an epirubicin blood sample is pretreated through an acetonitrile precipitation method and then dropwise added to the substrate to be dried away from light, and the 1236 cm <-1 > characteristic peak intensity is detected through a 785 nm Raman spectrum. By establishing a quantitative curve of epirubicin concentration and peak intensity in serum, rapid quantitative detection of clinical samples is realized. The method is simple in sample treatment, high in detection sensitivity, good in repeatability, consistent with LC-MS / MS results, and suitable for bedside treatment drug monitoring.

The application belongs to the field of medicine synthesis, and particularly relates to a chemical synthesis method of an epirubicin intermediate, daunorubicin. The daunorubicin is synthesized by taking 2,5-dihydroxybenzyl alcohol as raw material, the route has low raw material cost, mild reaction condition, convenient post-treatment, high total yield, and has a good industrial application prospect.

The application discloses a kind of endoplasmic reticulum of tumor cell can be targeted N -(2-hydroxypropyl) methacrylamide (HPMA) polymer-drug conjugate. The chemotherapeutic drug carried by the HPMA polymer is at least one of doxorubicin, epirubicin, pirarubicin, cisplatin, oxaliplatin, camptothecin, paclitaxel, gemcitabine, methotrexate, vinblastine, mitoxantrone, irinotecan, and the linker for connecting the drug and the HPMA polymer is at least one of hydrazone bond, amide bond, ester bond, disulfide bond, and ketosulfenyl bond. The HPMA polymer-drug conjugate targets the drug to the endoplasmic reticulum through receptor-ligand interaction, can cause severe endoplasmic reticulum stress, thereby transporting a large amount of calnexin to the tumor cell membrane surface, greatly improving the immunogenicity of tumor cells, and promoting tumor immunotherapy.

The invention discloses a pharmaceutical composition containing a polysialic acid-melittin polyion compound and sialic acid modified anthracycline anti-tumor drug liposome and application of the pharmaceutical composition. The invention belongs to the technical field of biological medicine, and particularly relates to a targeted delivery pharmaceutical composition for treating cold tumors through immunotherapy, and the pharmaceutical composition comprises a polysialic acid-melittin polyion compound and sialic acid modified anthracycline antitumor drug liposome. The anthracycline antitumor drug is selected from one or more of the following components: doxorubicin, epirubicin, pirarubicin, idarubicin, daunorubicin or mitoxantrone. The pharmaceutical composition shows a remarkable synergistic effect in tumor inhibition index, can stimulate congenital immunity and adaptive immunity, induce multiple release of tumor-associated antigens and specific antigens, trigger tumor immune circulation and recover immune control of a body on tumors, and also can enable the body to generate immune memory, so that the tumor inhibition effect is improved. And a new combined treatment strategy is provided for cold tumor treatment.

Provided is a novel crystallization method for epirubicin hydrochloride. Provided is a production method for crystals of epirubicin hydrochloride that includes (a) a step for obtaining a mixture that includes epirubicin hydrochloride, two alcohols, and water and (b) a step for adding an ether to the mixture obtained at step (a) and crystallizing the epirubicin hydrochloride. Also provided are novel crystals of epirubicin hydrochloride.

The invention relates to a pharmaceutical composition for preventing and / or treating tumors. The pharmaceutical composition comprises the following topoisomerase II inhibitors as active ingredients: doxorubicin, etoposide, idarubicin, anacridine, acarubicin, teniposide, epirubicin and pirarubicin. Compared with any one of the components, the pharmaceutical composition disclosed by the invention has a remarkable tumor inhibition effect, the toxic and side effects are obviously reduced, and all the components have a synergistic effect.

The present invention relates to a composition for diagnosing resistance to a combination of ECF (Epirubicin, Cisplatin and 5-Fluorouracil; ECF), which is used for the treatment of gastric cancer, and a diagnostic kit comprising the same. In order to solve a problem that cancer recurrence and drug resistance occur due to an increase in tumor initiating cells (TICs) after treatment with a drug belonging to the ECF family, NINJ2 may be inhibited by early detection of resistance appearance, thereby suppressing the recurrence of gastric cancer and treating resistance to the drugs.

The application discloses a prediction model training method for predicting the relative curative effects of EC and T in NAC, and the method comprises the following steps: acquiring MRI image data and clinical pathological data of a subject to construct a data set, and constructing an imageomics model based on DCE and ADC sequences through image segmentation, feature extraction, qualitative relative curative effect feature, model construction and verification, and a mixed model combined with clinical pathological factors is used to predict the relative curative effects of EC and T treatment. The application can effectively predict the relative curative effects of EC (epirubicin plus cyclophosphamide) and T (taxane drugs) treatment schemes in the middle stage of NAC, so as to timely adjust the treatment scheme and improve the treatment effect.

The present application relates to a kind of polypeptides, and specifically relates to a kind of tumor targeting peptide and its application;Tumor targeting peptide p46-2 is the carboxyl end of the 361-382 fragment of human cell tumor antigen p53 by connecting peptide and tumor targeting fragment arginine-glycine-aspartic acid-arginine connection;Chemotherapy drugs include paclitaxel, epirubicin, 5 fluorouracil;Selected tumor types include breast cancer, colorectal cancer.Tumor targeting polypeptide and classic chemotherapy drug combination therapy tumor, can obviously achieve the effect of drug synergism.

This invention provides a novel crystallization method for epirubicin hydrochloride. [Solution] A method for producing epirubicin hydrochloride crystals is provided, comprising the steps of (a) obtaining a mixture containing epirubicin hydrochloride, two types of alcohol, and water, and (b) adding ether to the mixture obtained in step (a) to crystallize the epirubicin hydrochloride. A novel crystal of epirubicin hydrochloride is also provided.

The invention discloses an epirubicin drug sensitive marker, a detection reagent and related application thereof. The epirubicin drug sensitive marker is an epirubicin drug-resistant marker or / and an epirubicin sensitive marker, and the epirubicin drug-resistant marker is one or more of SRD5A2, ATOH8, DCPS, DAPK2, PON1, TLR5 and NPTX1, and the epirubicin drug-sensitive marker is one or more of SRD5A2, ATOH8, DCPS, DAPK2, PON1, TLR5 and NPTX1. The epirubicin star sensitive marker is one or more of IGFBP3, CCZ1, TRIAP1, LSR, CCNE1, PCSK1N, NUDT5, CDKL2, LRRC73, RAC3 and DNAAF3 (deoxyribonucleic acid-associated protein 3). The epirubicin drug sensitive marker can be used for predicting the drug effect of epirubicin. According to the present invention, the expression of the related molecules is detected by sequencing the transcriptome of the tissue of the urothelium carcinoma patient, or by using the PC R, the gene chip, the tissue chip, the NanoString technology, the immunohistochemistry and the ELISA method, such that the clue can be provided for the medication of the epirubicin and the precise treatment of the bladder cancer.

(3R, 4S)-3-(4-hydroxy-3,5-dimethoxyphenyl)-4-(4-hydroxyphenyl)-8-methyl-3,4-dihydro-2H- chromen-7-ol (TRX-E-002-1) for use in a method of treatment for a hematological cancer being acute myeloid leukemia or multiple myeloma in a subject in need thereof, the method comprising administering to the subject an effective amount of TRX-E-002-1. The method may further comprise administering to the subject an effective amount of a second compound selected from the group consisting of (i) a BCL-2 inhibitor such as venetoclax, navitoclax or obatoclax, (ii) a deoxycytidine analogue chemotherapeutic such as cytarabine or gemcitabine, (iii) a hypomethylating agent such as azacitidine or decitabine, (iv) an anthracycline chemotherapeutic such as daunorubicin, doxorubicin, epirubicin, idarubicin, valrubicin or mitoxantrone, (v) a proteasome inhibitor such as carfilzomib, bortezomib, and ixazomib, (vi) an immunomodulatory drug such as pomalidomide, lenalidomide, and thalidomide and(vii) a corticosteroid drug such as dexamethasone or prednisone, and (viii) an alkylator such as bendamustine, cyclophosphamide, melphalan, and melflufen. Corresponding combination pharmaceutical compositions.